oncology

Floxuridine (FUDR) is an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity.

CG347B is a selective inhibitor of HDAC6.

EPZ020411 is a specific and effective inhibitor of PRMT6 (IC50=10 nM).

Anti-CD180 Antibody is an antibody targeting CD180. It can be used for tumor immunology, inflammation, and autoimmune disease research.

Numidargistat dihydrochloride (CB-1158 dihydrochloride) is an orally active and highly effective arginase (ARG1) inhibitor, an immuno-oncology agent that inhibits TGF-β2-induced subcapsular cataract by reducing the proliferation of lens epithelial cells (LEC) and decreasing the expression of fibronectin, α-SMA, collagen 1A1, and vimentin.

GSK864 is an IDH1 mutant inhibitor that inhibits IDH1 mutants R132C, R132H, and R132G, and is used in the study of cardiovascular and oncology diseases.

AZD-8055 is an orally bioavailable, highly selective, ATP-competitive mTOR kinase inhibitor that directly binds to the ATP-binding pocket of the mTOR kinase domain, while potently inhibiting both mTORC1 and mTORC2 complexes (IC₅₀ values of 0.8 nM and 0.1 nM, respectively). AZD-8055 is suitable for research in oncology, metabolic diseases, and fibrotic disorders.

Omaveloxolone (RTA-408) is an oral, potent, and selective activator of the nuclear factor erythropoietin-related factor 2 (Nrf2) pathway, as well as a low-potency PPARγ agonist. Omaveloxolone inhibits osteoclast formation by suppressing the STING-dependent NF-κB signaling pathway. Omaveloxolone is being investigated for use in ALS, multiple sclerosis, non-alcoholic steatohepatitis, neurodegenerative diseases, and oncology research.

Tarlatamab (AMG-757) is a bispecific T cell engager (BiTE) antibody targeting DLL3 and CD3, with human DLL3 and CD3 KD = 0.64 nM/14.9 nM, for use in immuno-oncology therapy of small cell lung cancer (SCLC).

ART558 is a potent, selective, low molecular weight, allosteric DNA polymerase activity of Polθ inhibitor (IC50=7.9 nM). ART558 can be used for the research of cancer.

Izonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.Izonsteride is used in the treatment of oncology and genitourinary disorders, and may be used in the study of prostate cancer.

GSK040, a potent and highly selective inhibitor of BET BD2, exhibits a pIC50 of 8.3, demonstrating over 5000-fold selectivity against BET BD1 (pIC50=4.6). This compound is primarily utilized in oncology and immunology research [1].This compound is unstable in powder form and other related salt forms are recommended.

L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid abundantly present in the human body and involved in numerous metabolic processes. It serves multiple functions as a nitrogen source donor, energy substrate, and antioxidant precursor. It can be used in cell biology, immunology, and oncology research.

Vitamin D3 (cholecalciferol) is a naturally occurring form of vitamin D; once metabolically activated, it can induce cellular differentiation and cancer cell proliferation. Vitamin D3 can be used to establish kidney stone models and is also an important research target in the fields of immunology and oncology.

2-Aminoethyl diphenylborinate (2-APB) is a cell-permeable inhibitor of IP3R and TRP channels. 2-Aminoethyl diphenylborinate also inhibits store-operated Ca2+ (SOC) channels and activates certain TRP channels (V1, V2, and V3). 2-Aminoethyl diphenylborinate also inhibits vasospasm. 2-Aminoethyl diphenylborinate can be used in research on calcium biology, cell signaling, oncology, and neurobiology.

ACLY Inhibitor 7 is a highly potent and selective small molecule inhibitor that exhibits exceptional inhibitory activity against human ATP citrate lyase (hACLY). ACLY Inhibitor 7 demonstrates an IC50 value of less than 1 nM as measured by the ADP-Glo assay, indicating its potential for metabolic disease and oncology research.

AF-399/42018025 is a small-molecule antagonist of CC chemokine receptor 4 (CCR4) utilized as a research tool to investigate CCR4-mediated immune cell trafficking, inflammatory signaling, and chemokine-driven disease mechanisms, supporting studies in immunology, oncology, and inflammatory disorder models.

GDC-2992 is a selective and orally active androgen receptor (AR) degradator that degrades AR (DC50 = 2.7 nM) and inhibits proliferation (IC50 = 9.7 nM) in VCaP cells, making it suitable for studying castration-resistant prostate cancer (CRPC).

BMS-986463 is a WEE1 kinase molecule gel degrader and a CRBN E3 ligase regulator (CELMoD). BMS-986463 significantly inhibits tumor regression and reduces the level of phosphorylated CDK2. BMS-986463 is utilized in oncology research involving cell-cycle checkpoint regulation, protein degradation pathways, and malignant solid tumor models including non-small cell lung cancer (NSCLC).

MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor with IC50 = 4.4 nM and Ki = 0.16 nM. MI-1061 activates p53 and induces apoptosis in SJSA-1 xenograft tumor tissue in mice and is utilized in oncology research focused on p53 signaling regulation, MDM2-mediated tumor suppressor suppression, and apoptosis pathway activation in xenograft tumor models.

CA-170 is an orally bioavailable dual inhibitor of VISTA and PD-L1 that selectively restores T-cell proliferation and effector function suppressed by immune checkpoint signaling, while demonstrating minimal off-target activity across a broad receptor and enzyme panel, making CA-170 a valuable compound for immuno-oncology research and immune checkpoint modulation studies.

RIG-1 modulator 1 is an effective RIG-1 agonist. It induces IFN-β expression via innate immune activation, used for antiviral and immuno-oncology research.

ABTL-0812 (α-Hydroxylinoleic acid) is a first-in-class small-molecule compound that induces endoplasmic reticulum stress–mediated autophagy, leading to cancer cell death, ABTL-0812 is extensively applied in oncology research to investigate ER stress signaling, autophagic cell death pathways, and novel anticancer mechanisms with translational therapeutic potential.

BDP FL DBCO is a cleavable linker molecule critical for antibody-drug conjugate (ADC) synthesis. BDP FL DBCO enables the covalent attachment of cytotoxic drugs to antibodies, ensuring targeted delivery to cells or proteins, and the cleavable nature facilitates controlled drug release, optimizing the pharmacodynamic effectiveness of ADCs in oncology studies.